Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00954278 | Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 24 | University of Wisconsin, MadisonOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT01478685 | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 169 | CelgeneINDUSTRY | 4 | Nov 12, 2019 | clinicaltrials |
| NCT01545947 | Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer | completed | Phase 1 | 76 | CelgeneINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
| NCT02367443 | Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC | unknown | Phase 1 / Phase 2 | 92 | Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology CentreOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT02000947 | A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer(D4190C00006) | completed | Phase 1 | 459 | MedImmune LLCINDUSTRY | 9 | Oct 31, 2019 | clinicaltrials |
| NCT03910127 | Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） | unknown | Phase 1 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT02448251 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer | terminated | Phase 1 | 28 | ACEA Therapeutics, Inc.INDUSTRY | 3 | Oct 29, 2019 | clinicaltrials |
| NCT03780010 | Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC | completed | Phase 1 | 15 | Tracon Pharmaceuticals Inc.INDUSTRY | 0 | Oct 28, 2019 | clinicaltrials |
| NCT04133337 | Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | unknown | Phase 1 / Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02920450 | Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | terminated | Phase 1 / Phase 2 | 3 | University of FloridaOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT03101839 | Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours | completed | Phase 1 | 28 | AstraZenecaINDUSTRY | 2 | Oct 4, 2019 | clinicaltrials |
| NCT03982134 | PDR001 + Panobinostat for Melanoma and NSCLC | withdrawn | Phase 1 | 0 | Muhammad FurqanOTHER | 0 | Oct 4, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT00037817 | Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT03396497 | Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer | unknown | Phase 1 | 17 | Lycera Corp.INDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT02603003 | the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs(CTC-TCM-FZ) | completed | Phase 1 | 218 | Shanghai University of Traditional Chinese MedicineOTHER | 0 | Sep 20, 2019 | clinicaltrials |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 | clinicaltrials |
| NCT02843815 | Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02845856 | Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01259089 | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT04059874 | Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate | unknown | Phase 1 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT03029871 | Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer(NSCLC) | withdrawn | Phase 1 | 0 | Benjamin Movsas, M.D.OTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT02128724 | Palliative Thoracic Radiotherapy Plus BKM120(BKM120) | completed | Phase 1 | 21 | University of OxfordOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT03510611 | A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers. | completed | Phase 1 | 24 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 24, 2019 | clinicaltrials |
| NCT01837329 | Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer | completed | Phase 1 | 26 | University of RochesterOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02914990 | Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients | completed | Phase 1 | 36 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | terminated | Phase 1 / Phase 2 | 13 | PrECOG, LLC.OTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT03366064 | Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)(Medi-NK) | completed | Phase 1 | 5 | Asan Medical CenterOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT02630186 | A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC | terminated | Phase 1 / Phase 2 | 3 | Clovis Oncology, Inc.INDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT00714246 | Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 6 | Milton S. Hershey Medical CenterOTHER | 1 | Jun 24, 2019 | clinicaltrials |
| NCT03726736 | Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC(ACWDVDFPTAN) | unknown | Phase 1 / Phase 2 | 97 | Yong FangOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT00582283 | NM404 as an Imaging Agent in Patients With NSCLC | completed | Phase 1 | 21 | University of Wisconsin, MadisonOTHER | 1 | May 22, 2019 | clinicaltrials |
| NCT02069158 | Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor(IOSI-NDU-001) | completed | Phase 1 | 17 | Cristiana SessaOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT00387465 | Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | May 9, 2019 | clinicaltrials |
| NCT01664754 | Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer | completed | Phase 1 | 8 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT02080078 | A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline | terminated | Phase 1 | 15 | AHS Cancer Control AlbertaOTHER | 1 | May 3, 2019 | clinicaltrials |
| NCT00793208 | Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 1 | Theresa Whiteside, PhDOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT03166254 | Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Apr 12, 2019 | clinicaltrials |
| NCT03903887 | A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT02145637 | Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 30 | Yonsei UniversityOTHER | 0 | Mar 29, 2019 | clinicaltrials |
| NCT01069575 | Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 18 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01069640 | Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 9 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01949701 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01950156 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01283516 | A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase | completed | Phase 1 | 304 | Novartis PharmaceuticalsINDUSTRY | 11 | Mar 15, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Nov 15, 2019source: clinicaltrials